Predictors of unfavorable long-term prognosis after percutaneous coronary intervention in patients with chronic obstructive pulmonary disease and acute coronary syndrome

Aim. Тo determine independent predictors of unfavorable cardiovascular long-term prognosis after percutaneous coronary intervention in patients with acute coronary syndrome and concomitant chronic obstructive pulmonary disease.

Methods. 119 patients with acute coronary syndrome after percutaneous coronary intervention and concomitant chronic obstructive pulmonary disease were included in prospective cohort study. During follow-up up to 36 month the frequency of major cardiovascular events (cardiovascular death, myocardial infarction, stroke, repeat myocardial revascularization) were registered. The predictors of combined end point were identified by Cox regression through forward stepwise mode.

Results. Independent variables as major cardiovascular events predictors were determined: main coronary arteries stenosis number, ankle-brachial index, glomerular filtration rate according to the CKD-EPI formula, frequent COPD exacerbations, functional residual lung capacity, 6-minute walk test distance.

Conclusion. Functional residual lung capacity as a lung hyperinflation indicator and frequent COPD exacerbations are among independent predictors of major cardiovascular events in long-term follow-up period after percutaneous coronary intervention in patients with acute coronary syndrome and concomitant chronic obstructive pulmonary disease.

1. Neumann F.J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/ EACTS Guidelines on myocardial revascularization. Eur. Heart J.2019; 40 (2): 87-165. DOI: 10.1093/eurheartj/ehy394.

2. Grigor'eva N.Yu., Kuznetsov A.N., Sharabrin E.G. [The place of chronic obstructive pulmonary disease in the development of the cardiovascular continuum]. Serdtse: zhurnal dlya praktikuyushchikh vrachey. 2012; 11 (2): 120-122 (in Russian).

3. Avdeev S.N. [COPD as a systemic disease]. Pul’monologiya. 2007; (2): 104-116. DOI: 10.18093/0869-0189-2007-0-2104-116 (in Russian).

4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2019 Report. Available at: https://gold-copd.org/wp-content/uploads/2G18/11/GOLD-2G19-v1.7-FINAL-14Nov2018-WMS.pdf [Accessed: April 29, 2019].

5. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2011 Report. Available at: http://www.gold-copd.org/ [Accessed: December 14, 2018].

6. Cheng J.M., Oemrawsingh R.M., Garcia-Garcia H.M. et al. Relation of C-reactive protein to coronary plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovascular outcome in patients with acute coronary syndrome or stable angina pectoris (from the ATHERORE-MO-IVUS study). Am. J. Cardiol. 2014; 114 (10): 1497-1503. DOI: 10.1016/j.amjcard.2014.08.013.

7. Mohr F.W., Morice M.C., A. P. Kappetein A.P. et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013; 381 (9867): 629-638. DOI: 10.1016/S0140-6736(13)60141-5.

8. Ankle brachial index combined with framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008; 300 (2):197-208. DOI: 10.1001/jama.300.2.197.

9. Bonaca M.P., Bhatt D.L., Storey R.F. et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J. Am. Coll. Cardiol. 2016; 67 (23): 2719-2728. DOI: 10.1016/j.jacc.2016.03.524.

10. Shah M.R., Hasselblad V., Gheorghiade M. et al. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am. J. Cardiol. 2001; 88 (9): 987-993. DOI: 10.1016/s0002-9149(01)01975-0.

11. Swiston J.R., Johnson S.R., Granton J.T. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature. Respir. Med. 2010; 104 (11): 1588-1607. DOI: 10.1016/j.rmed.2010.08.003.

12. Pinto-Plata V.M., Cote C., Cabral H. et.al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur. Respir. J. 2004; 23 (1): 28-33. DOI: 10.1183/09031936.03.00034603.

13. Beatty A.L., Schiller N.B., Whooley M.A. Six-minute walk test as a prognostic tool in stable coronary heart disease: data from the heart and soul study. Arch. Intern. Med. 2012; 172 (14): 1096-1102. DOI: 10.1001/archinternmed.2012.2198.

14. Hassan A.K., Dimitry S.R., Agban G.W. Can exercise capacity assessed by the 6 minute walk test predict the development of major adverse cardiac events in patients with STEMI after fibrinolysis? PLoS One. 2014; 9 (6): e99035. DOI: 10.1371/journal.pone.0099035.

15. Schiffrin E.L., Lipman M.L., Mann J.F.E. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007; 116 (1): 85-97. DOI: 10.1161/CIRCULATIONAHA.106.678342.

16. Savushkina O.I., Chernyak A.V. [Theoretical and methodological aspects of body plethysmography and clinical applications]. Byulleten'fiziologii ipatologii dykhaniya. 2016; 60: 117-124. DOI: 10.12737/20131 (in Russian).

17. Budweiser S., Harlacher M., Pfeifer M., Jorres R.A. Comorbidities and hyperinflation are independent risk factors of all-cause mortality in very severe COPD. COPD. 2014; 11 (4): 388-400. DOI: 10.3109/15412555.2013.836174.

18. Casanova C., Cote C., de Torres J.P. et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171 (6): 591-597. DOI: 10.1164/rccm.200407-867OC.

19. Smith B.M., Prince M.R., Hoffman E.A. et al. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic study of Atherosclerosis COPD study. Chest. 2013; 144 (4): 1143-1151. DOI: 10.1378/chest.13-0183.

20. Vivodtzev I., Tamisier R., Baguet J.P. et al. Arterial stiffness in COPD. Chest. 2014; 145 (4): 861-875. DOI: 10.1378/chest.13-1809.

21. Barr R.G., Mesia-Vela S., Austin J.H.M. et al. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) study. Am. J. Respir. Crit. Care Med. 2007; 176 (12): 1200-1207. DOI: 10.1164/rccm.200707-980OC.

22. Maclay J.D., McAllister D.A., Mills N.L. et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180 (6): 513-520. DOI: 10.1164/rccm.200903-0414OC.

23. Mineo D., Ambrogi V., Cufari M.E. et al. Variations of inflammatory mediators and alpha1-antitrypsin levels after lung volume reduction surgery for emphysema. Am. J. Respir. Crit. Care Med. 2010; 181 (8): 806-814. DOI: 10.1164/rccm.200910-1476OC.

24. King P.T. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin. Transl. Med. 2015; 4 (1): e26. DOI: 10.1186/s40169-015-0068-z.

25. Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67 (11): 957-963. DOI: 10.1136/thoraxjnl-2011-201518.

26. Libby P., Tabas I., Fredman G., Fisher E.A. Inflammation and its resolution as determinants of acute coronary syndromes. Circ. Res. 2014; 114 (12): 1867-1879. DOI: 10.1161/CIRCRESAHA.114.302699.

27. Roversi S., Roversi P., Spadafora G. et al. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur. J. Clin. Invest. 2014; 44 (1): 93-102. DOI: 10.1111/eci.12181.

28. van Diepen J.A., Berb6e J.F.P., Havekes L.M., Rensen P.C.N. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis. 2013; 228 (2): 306-315. DOI: 10.1016/j.atherosclerosis.2013.02.028.

29. Alekseeva O.V., Demko I.V., Shnayder I.A., Petrova M.M. [Comorbidity of obstructive sleep apnea/hypopnea syndrome and chronic obstructive pulmonary disease]. Zabaykal’skiy meditsinskiy vestnik. 2016; (2): 107-114 (in Russian).

30. Criner G.J., Connett J.E., Aaron S.D. et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N. Eng. J. Med. 2014; 370 (23): 2201-2210. DOI: 10.1056/NEJMoa1403086.